Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid Tumours
Phase 1
Completed
- Conditions
- Solid Tumors
- Interventions
- Biological: TB-403
- Registration Number
- NCT00702494
- Lead Sponsor
- BioInvent International AB
- Brief Summary
TB-403 is a monoclonal antibody directed against Placental Growth Factor (PlGF). The antibody binds to PlGF and inhibits the binding to it's receptor, VEGF-1. By preventing this binding, growth of tumor vessels are inhibited and tumor growth prevented.
In this study we are investigating the tolerability and safety of TB-403 in patients with solid tumors who receives multiple intravenous doses of TB-403.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 21
Inclusion Criteria
- Confirmed malignity
- Measurable disease
- Performance status 1 or less (ECOG)
Exclusion Criteria
- Acute illness or infection
- Concurrent second malignancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 1 TB-403 Multiple IV doses of TB-403, an antibody directed against PlGF
- Primary Outcome Measures
Name Time Method Safety and tolerability of an anti-PlGF antibody 85 days
- Secondary Outcome Measures
Name Time Method Determine multiple dose IV pharmacokinetics 85 days
Trial Locations
- Locations (2)
Onkologisk Klinik 5072 Finsencentret Rigshospitalet
🇩🇰Copenhagen, Denmark
Onkologisk Afdeling 54B1 Herlev Hospital
🇩🇰Herlev, Denmark